| Cat. No. |
Size |
Price |
Figures |
|---|
RP13497-0.2 mg
| 0.2 mg | $ 33.25 | MSDS: 20080909223140 (PDF)
References:
- Rai A, et al. Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. Exp. Biol. Med. (Maywood). Jun 2006; 231(6): 1120-1122.
- Rossi NF, et al. Nitric oxide modulation of ET(B) receptor-induced vasopressin release by rat and mouse hypothalamo-neurohypophyseal explants. Am. J. Physiol. Regul. Integr. Comp. Physiol. May 2006; 290(5): R1208-1215.
- Wang X, et al. Hypoxia-induced reactive oxygen species downregulate ETB receptor-mediated contraction of rat pulmonary arteries. Am. J. Physiol. Lung Cell Mol. Physiol. Mar 2006; 290(3): L570-578.
|
|---|
| Full Name | |
| Alias |
IRL-1620; IRL1620 |
Sequence
(three-letter code) | Suc-[Glu9Ala11,15]-Endothelin-1(8-21)Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp |
|---|
| Description | IRL-1620 significantly enhanced delivery and effectiveness of paclitaxel in an animal model of breast cancer. IRL-1620 together with IRL-1038 (Prod. No. ALX-155-007) is an indispensable pharmacological tool to assess the participation of the ETB receptor in some pathophysiological phenomena, by selectively stimulating ETB receptor-mediated responses in various pathophysiological models established in vitro and in vivo. |
|---|
| Solubility | Insoluble in water. Dissolve the content with > pH 8.5 buffer. |
|---|
| Formula | C86H117N17O27 |
|---|
| M.W. | 1820.95 |
|---|
| Cas | 142569-99-1 |
|---|
| Purity | > 95% |
|---|
| Storage | Store at -20°C. |
| Notes | This peptide is most potent and specific ligand for the ETB receptor (KiETA/KiETB=120 000) as judged by the Ki values for ETA (1.9 µM) and ETB (16 pM) receptors. IRL1620 (10-9-10-7 µM) induced contraction of the guinea pig tracheal with a comparable potency to those of ET-1 or ET-3. |
|---|
